<?xml version='1.0' encoding='utf-8'?>
<document id="29723418"><sentence text="Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects."><entity charOffset="18-27" id="DDI-PubMed.29723418.s1.e0" text="Rifabutin" /><entity charOffset="47-57" id="DDI-PubMed.29723418.s1.e1" text="Doravirine" /><pair ddi="false" e1="DDI-PubMed.29723418.s1.e0" e2="DDI-PubMed.29723418.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s1.e0" e2="DDI-PubMed.29723418.s1.e1" /></sentence><sentence text="Doravirine is a nonnucleoside reverse transcriptase inhibitor in clinical development for the treatment of human immunodeficiency virus-1 infection in combination with other antiretroviral therapies"><entity charOffset="0-10" id="DDI-PubMed.29723418.s2.e0" text="Doravirine" /></sentence><sentence text=" The cytochrome P450 (CYP)3A-dependent metabolism of doravirine makes it susceptible to interactions with modulators of this pathway, including the antituberculosis treatment rifampin"><entity charOffset="53-63" id="DDI-PubMed.29723418.s3.e0" text="doravirine" /><entity charOffset="175-183" id="DDI-PubMed.29723418.s3.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.29723418.s3.e0" e2="DDI-PubMed.29723418.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s3.e0" e2="DDI-PubMed.29723418.s3.e1" /></sentence><sentence text=" Rifabutin, an alternative antibiotic used to treat tuberculosis, may have a lower-magnitude effect on CYP3A"><entity charOffset="1-10" id="DDI-PubMed.29723418.s4.e0" text="Rifabutin" /></sentence><sentence text=" The aim of this trial was to determine the effect of steady-state rifabutin on doravirine single-dose pharmacokinetics and tolerability"><entity charOffset="67-76" id="DDI-PubMed.29723418.s5.e0" text="rifabutin" /><entity charOffset="80-90" id="DDI-PubMed.29723418.s5.e1" text="doravirine" /><pair ddi="false" e1="DDI-PubMed.29723418.s5.e0" e2="DDI-PubMed.29723418.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s5.e0" e2="DDI-PubMed.29723418.s5.e1" /></sentence><sentence text=" In this open-label, 2-period, fixed-sequence, drug-drug interaction study, healthy subjects received a single dose of doravirine 100 mg alone and coadministered on day 14 of once-daily administration of rifabutin 300 mg for 16 days"><entity charOffset="119-129" id="DDI-PubMed.29723418.s6.e0" text="doravirine" /><entity charOffset="204-213" id="DDI-PubMed.29723418.s6.e1" text="rifabutin" /><pair ddi="false" e1="DDI-PubMed.29723418.s6.e0" e2="DDI-PubMed.29723418.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s6.e0" e2="DDI-PubMed.29723418.s6.e1" /></sentence><sentence text=" Plasma samples were taken to determine doravirine pharmacokinetics, and safety was monitored throughout" /><sentence text=" Dose adjustment of doravirine in the presence of coadministered rifabutin was explored through nonparametric superposition analysis"><entity charOffset="20-30" id="DDI-PubMed.29723418.s8.e0" text="doravirine" /><entity charOffset="65-74" id="DDI-PubMed.29723418.s8.e1" text="rifabutin" /><pair ddi="false" e1="DDI-PubMed.29723418.s8.e0" e2="DDI-PubMed.29723418.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s8.e0" e2="DDI-PubMed.29723418.s8.e1" /></sentence><sentence text=" Rifabutin reduced doravirine area under the concentration-time curve from time zero to infinite and plasma drug concentration 24 hours postdose with geometric mean ratios ([rifabutin+doravirine]/[doravirine alone]) (90%CIs) of 0"><entity charOffset="1-10" id="DDI-PubMed.29723418.s9.e0" text="Rifabutin" /><entity charOffset="19-29" id="DDI-PubMed.29723418.s9.e1" text="doravirine" /><pair ddi="false" e1="DDI-PubMed.29723418.s9.e0" e2="DDI-PubMed.29723418.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s9.e0" e2="DDI-PubMed.29723418.s9.e1" /></sentence><sentence text="50 (0" /><sentence text="45-0" /><sentence text="55) and 0" /><sentence text="32 (0" /><sentence text="28-0" /><sentence text="35), respectively" /><sentence text=" Doravirine apparent clearance increased from 5"><entity charOffset="1-11" id="DDI-PubMed.29723418.s16.e0" text="Doravirine" /></sentence><sentence text="9 L/h without rifabutin to 12"><entity charOffset="14-23" id="DDI-PubMed.29723418.s17.e0" text="rifabutin" /></sentence><sentence text="2 L/h when coadministered" /><sentence text=" Doravirine pharmacokinetics with and without coadministered rifabutin were not equivalent"><entity charOffset="1-11" id="DDI-PubMed.29723418.s19.e0" text="Doravirine" /><entity charOffset="61-70" id="DDI-PubMed.29723418.s19.e1" text="rifabutin" /><pair ddi="false" e1="DDI-PubMed.29723418.s19.e0" e2="DDI-PubMed.29723418.s19.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s19.e0" e2="DDI-PubMed.29723418.s19.e1" /></sentence><sentence text=" Nonparametric superposition analysis projected that administration of doravirine 100 mg twice daily with rifabutin will restore steady-state trough concentration values to efficacious levels associated with doravirine 100 mg once daily in the absence of CYP3A inducers"><entity charOffset="71-81" id="DDI-PubMed.29723418.s20.e0" text="doravirine" /><entity charOffset="106-115" id="DDI-PubMed.29723418.s20.e1" text="rifabutin" /><entity charOffset="208-218" id="DDI-PubMed.29723418.s20.e2" text="doravirine" /><pair ddi="false" e1="DDI-PubMed.29723418.s20.e0" e2="DDI-PubMed.29723418.s20.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s20.e0" e2="DDI-PubMed.29723418.s20.e1" /><pair ddi="false" e1="DDI-PubMed.29723418.s20.e0" e2="DDI-PubMed.29723418.s20.e2" /><pair ddi="false" e1="DDI-PubMed.29723418.s20.e1" e2="DDI-PubMed.29723418.s20.e1" /><pair ddi="false" e1="DDI-PubMed.29723418.s20.e1" e2="DDI-PubMed.29723418.s20.e2" /></sentence><sentence text=" Doravirine may be coadministered with rifabutin when the doravirine dose frequency is increased from 100 mg once daily to 100 mg twice daily"><entity charOffset="1-11" id="DDI-PubMed.29723418.s21.e0" text="Doravirine" /><entity charOffset="39-48" id="DDI-PubMed.29723418.s21.e1" text="rifabutin" /><entity charOffset="58-68" id="DDI-PubMed.29723418.s21.e2" text="doravirine" /><pair ddi="false" e1="DDI-PubMed.29723418.s21.e0" e2="DDI-PubMed.29723418.s21.e0" /><pair ddi="false" e1="DDI-PubMed.29723418.s21.e0" e2="DDI-PubMed.29723418.s21.e1" /><pair ddi="false" e1="DDI-PubMed.29723418.s21.e0" e2="DDI-PubMed.29723418.s21.e2" /><pair ddi="false" e1="DDI-PubMed.29723418.s21.e1" e2="DDI-PubMed.29723418.s21.e1" /><pair ddi="false" e1="DDI-PubMed.29723418.s21.e1" e2="DDI-PubMed.29723418.s21.e2" /></sentence><sentence text="" /></document>